Printer Friendly

Abarelix, SERMs, Extracellular Matrix Modulators, Terbutaline and RU486 are expected to drive Endometriosis market growth: companiesandmarkets.com.

LONDON -- * Global endometriosis market forecast to total US$1.3 billion by 2017

* Angiogenesis therapy expected to emerge as a key treatment option

* Future drugs include: Abarelix, SERMs (Selective Estrogen Receptor Modulators), Extracellular Matrix Modulators, Terbutaline, and RU-486.

Endometriosis is a condition which is estimated to affect over 170 million women of reproductive age, with associated healthcare costs and losses in productivity amounting to around $4,000 a year; according to a new report on companiesandmarkets.com. Worldwide, it is forecast that the treatment market for endometriosis will achieve a value of $1.3 billion by 2017.

Endometriosis: A Global Strategic Business Report

http://www.companiesandmarkets.com/Market-Report/endometriosis-a-global-strategic-business-report-618283.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

Growth in the endometriosis market is being driven by increased incidence of the disease which is linked to improvements in its diagnosis. There is a distinct unmet need for safe and effective drugs, as many existing treatments are linked with unwelcome side effects. The largest geographic market is the US, followed by Europe. The 'Rest of World' geographic market is likely to grow fastest over the forecast period, at 6% annually.

Current treatment options for endometriosis include contraceptives, NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Progestins and GnRH (Gonadotropin-Releasing Hormone) agonists. Pfizer's Synarel and Depo-Provera, are the most common drugs used in the treatment of the disease, as is Lupron Depot - a GnRH - by Abbot.

Future endometriosis treatments include Abarelix, undergoing US clinical trials; Proellex - a progesterone activity blocker by Repros Therapeutics; Neurocrine's Elagolix - an oral non-peptide GnHR; and Visanne by Bayer HealthCare Pharmaceuticals.

Invasive laparoscopy is the main technique used for diagnosis of endometriosis, although non-invasive diagnostics such as MRIs, biomolecular and genetic testing are likely to grow in popularity as technologies develop.

Some of the 32 key players profiled within the endometriosis market report include Pfizer Inc; Abbott Laboratories; Repros Therapeutics Inc; Aeterna Zentaris Inc; Paladin Labs Inc; AstraZeneca Plc; Eli Lilly and Company; Meditrina Pharmaceuticals Inc; Bayer HealthCare Pharmaceuticals Inc and Neurocrine Biosciences Inc.

The report comprises 346 pages of strategic information about the endometriosis treatment market, including forecast data to 2017. In addition to summarising the market, the report includes information relating to current and pipeline treatments; trends; market drivers/barriers; regulations and other market-influencing factors.

Report Details:

http://www.companiesandmarkets.com/Market-Report/endometriosis-a-global-strategic-business-report-618283.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2
COPYRIGHT 2011 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:4EUUK
Date:Jun 20, 2011
Words:452
Previous Article:gamerDNA Media Invites Gamers to Celebrate Gears of War 3 Launch with Brotherhood Achievement Challenge.
Next Article:Core Security Recognized for Innovation and Company Performance with 2011 Red Herring Top 100 Award.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters